Spine surgery firm SMAIO 2025 sales surge 67%

SMAIO SA

20/01/2026 16:58

Overview

French-American spine surgery firm's 2025 sales rose 67% yr/yr to €9.2 mln

Signed two major partnerships for KEOPS-4ME platform in 2025

Outlook

Company expects sustained growth in U.S. market in 2026

SMAIO aims to finalize additional partnerships for K-Rods in 2026

Result Drivers

U.S. SALES GROWTH - U.S. sales rose by 138% to €7 mln, driven by adoption of the Kheiron system for complex spine surgeries

NEW PARTNERSHIPS - Two major partnerships for KEOPS-4ME platform signed

PROCEDURE INCREASE - Kheiron system procedures in U.S. rose to 326 from 180, supporting premium pricing

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Sales
Miss
EUR 9.20 mln
EUR 9.95 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for SMAIO SA is €8.10, about 10.2% above its January 19 closing price of €7.35

The stock recently traded at 43 times the next 12-month earnings vs. a P/E of 83 three months ago

Press Release: ID:nBw6P1bpxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)